Additionally, in hepatocellular carcinoma, Mel enhances the chemosensitivity of cancer cells to cisplatin by regulating the AP‐2β/hTERT and NF‐κB/COX‐2 signalling pathways [45]. Here, TFAP2B is linked to hepatocellular carcinoma.